Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review.

Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, Neamatallah TA, Ashour OM.

J Adv Res. 2017 Nov;8(6):591-605. doi: 10.1016/j.jare.2017.06.006. Epub 2017 Jun 27. Review.

2.

Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring.

Liang K, Liu F, Fan J, Sun D, Liu C, Lyon CJ, Bernard DW, Li Y, Yokoi K, Katz MH, Koay EJ, Zhao Z, Hu Y.

Nat Biomed Eng. 2017;1. pii: 0021. doi: 10.1038/s41551-016-0021. Epub 2017 Feb 6.

3.

Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.

Song W, Hwang Y, Youngblood VM, Cook RS, Balko JM, Chen J, Brantley-Sieders DM.

Oncogene. 2017 Oct 5;36(40):5620-5630. doi: 10.1038/onc.2017.170. Epub 2017 Jun 5.

4.

Epha3 acts as proangiogenic factor in multiple myeloma.

Caivano A, La Rocca F, Laurenzana I, Annese T, Tamma R, Famigliari U, Simeon V, Trino S, De Luca L, Villani O, Berardi S, Basile A, Vacca A, Saglio G, Del Vecchio L, Musto P, Cilloni D.

Oncotarget. 2017 May 23;8(21):34298-34309. doi: 10.18632/oncotarget.16100.

5.

EphA2 is a functional receptor for the growth factor progranulin.

Neill T, Buraschi S, Goyal A, Sharpe C, Natkanski E, Schaefer L, Morrione A, Iozzo RV.

J Cell Biol. 2016 Dec 5;215(5):687-703. Epub 2016 Nov 30.

6.

Mutational load and mutational patterns in relation to age in head and neck cancer.

Meucci S, Keilholz U, Tinhofer I, Ebner OA.

Oncotarget. 2016 Oct 25;7(43):69188-69199. doi: 10.18632/oncotarget.11312.

7.

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.

Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J.

Cancer Res. 2016 Jan 15;76(2):305-18. doi: 10.1158/0008-5472.CAN-15-0717. Epub 2016 Jan 7.

8.

Anti-angiogenic alternatives to VEGF blockade.

Khan KA, Bicknell R.

Clin Exp Metastasis. 2016 Feb;33(2):197-210. doi: 10.1007/s10585-015-9769-3. Epub 2015 Nov 30. Review.

9.

Advanced research on vasculogenic mimicry in cancer.

Qiao L, Liang N, Zhang J, Xie J, Liu F, Xu D, Yu X, Tian Y.

J Cell Mol Med. 2015 Feb;19(2):315-26. doi: 10.1111/jcmm.12496. Epub 2015 Jan 19. Review.

10.

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, Gray NS, Tsao H.

Cancer Discov. 2015 Mar;5(3):274-87. doi: 10.1158/2159-8290.CD-14-0295. Epub 2014 Dec 26.

11.

Elevated Slit2 Activity Impairs VEGF-Induced Angiogenesis and Tumor Neovascularization in EphA2-Deficient Endothelium.

Youngblood V, Wang S, Song W, Walter D, Hwang Y, Chen J, Brantley-Sieders DM.

Mol Cancer Res. 2015 Mar;13(3):524-37. doi: 10.1158/1541-7786.MCR-14-0142. Epub 2014 Dec 12.

12.

Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy.

Donnard E, Asprino PF, Correa BR, Bettoni F, Koyama FC, Navarro FC, Perez RO, Mariadason J, Sieber OM, Strausberg RL, Simpson AJ, Jardim DL, Reis LF, Parmigiani RB, Galante PA, Camargo AA.

Oncotarget. 2014 Oct 15;5(19):9199-213.

13.

EphA2-receptor deficiency exacerbates myocardial infarction and reduces survival in hyperglycemic mice.

DuSablon A, Kent S, Coburn A, Virag J.

Cardiovasc Diabetol. 2014 Aug 13;13:114. doi: 10.1186/s12933-014-0114-y.

14.

Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines.

Davidson BA, Rubatt JM, Corcoran DL, Teoh DK, Bernardini MQ, Grace LA, Soper WJ, Berchuck A, Siamakpour-Reihani S, Chen W, Owzar K, Murphy SK, Secord AA.

Front Oncol. 2014 Jun 20;4:163. doi: 10.3389/fonc.2014.00163. eCollection 2014.

15.

Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies.

Leto SM, Trusolino L.

J Mol Med (Berl). 2014 Jul;92(7):709-22. doi: 10.1007/s00109-014-1161-2. Epub 2014 May 10. Review.

16.
17.

Deletion of the EphA2 receptor exacerbates myocardial injury and the progression of ischemic cardiomyopathy.

O'Neal WT, Griffin WF, Kent SD, Faiz F, Hodges J, Vuncannon J, Virag JA.

Front Physiol. 2014 Apr 24;5:132. doi: 10.3389/fphys.2014.00132. eCollection 2014.

18.

Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.

Amato KR, Wang S, Hastings AK, Youngblood VM, Santapuram PR, Chen H, Cates JM, Colvin DC, Ye F, Brantley-Sieders DM, Cook RS, Tan L, Gray NS, Chen J.

J Clin Invest. 2014 May;124(5):2037-49. doi: 10.1172/JCI72522. Epub 2014 Apr 8.

19.

Roles of EphA2 in Development and Disease.

Park JE, Son AI, Zhou R.

Genes (Basel). 2013 Jul 1;4(3):334-57. doi: 10.3390/genes4030334.

20.

JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer.

Song W, Ma Y, Wang J, Brantley-Sieders D, Chen J.

Cancer Res. 2014 May 1;74(9):2444-54. doi: 10.1158/0008-5472.CAN-13-2136. Epub 2014 Mar 7.

Supplemental Content

Support Center